Skip to content

2005 Press Releases

Dec 20, 2005

Allergan and Inamed Execute Definitive Merger Agreement  

Dec 16, 2005

Allergan Extends Expiration Date of Exchange Offer for Inamed Corporation  

Dec 16, 2005

Allergan Requests Temporary Restraining Order and Preliminary Injunction in ACULAR(R) Patent Infringement Case; Seeks Ban on Sale of Proposed Generic Drug Pending Court Ruling  

Dec 13, 2005

Allergan Welcomes Inamed's Recommendation of Its Offer to Stockholders; Parties Look to Execute Merger Agreement and Close Transaction  

Dec 6, 2005

Allergan Completes Negotiation of Terms and Conditions of Merger Agreement with Inamed and Inamed Board of Directors Has Concluded that Allergan's Offer is Superior  

Nov 21, 2005

Allergan, Inc. Commences Exchange Offer for Shares of Inamed Corporation  

Nov 16, 2005

Allergan Comments on Inamed Statement  

Nov 15, 2005

Allergan, Inc. Proposes to Acquire Inamed Corporation for $84 Per Share; Acquisition to Create a World Leading Franchise in High-Growth Medical Aesthetics; Expands Allergan's Position as Premier Specialty Pharmaceutical Company  

Nov 1, 2005

Allergan Reports Third Quarter Operating Results and Increases Full Year Earnings Guidance; Pharmaceutical Sales Increased 25 Percent for the Third Quarter; Board of Directors Declares Third Quarter Dividend  

Oct 26, 2005

Allergan Announces Revised Date for Quarterly Conference Call  

Oct 13, 2005

Allergan Announces Quarterly Conference Call  

Oct 3, 2005

Allergan Enters Into Agreement with GlaxoSmithKline to Accelerate BOTOX(R) Development and Commercialization in Japan and China, Co-Promote IMITREX STATdose System(R) and AMERGE(R) in U.S.  

Sep 28, 2005

Allergan Receives Positive Opinions for COMBIGAN(TM) from 21 Countries in European Union  

Aug 23, 2005

Jeffrey Edwards Promoted to Executive Vice President, Finance and Business Development, Chief Financial Officer as Eric Brandt Resigns to Accept Position as President and Chief Executive Officer of Avanir Pharmaceuticals  

Aug 19, 2005

New Formulation of Allergan's ALPHAGAN(R) P Receives U.S. FDA Approval  

Jul 27, 2005

Allergan Reports Second Quarter Operating Results and Increases Full Year Earnings Guidance  

Jul 1, 2005

Allergan Announces Quarterly Conference Call  

Jun 23, 2005

Additional Data From Exploratory Phase II Studies Of Botox® (Botulinum Toxin Type A) As A Preventive Migraine/Headache Treatment To Be Presented At The American Headache Society's Annual Meeting  

Jun 1, 2005

Allergan Receives Written Response from FDA on Oral Tazarotene  

May 19, 2005

Louis J. Lavigne, Jr. Appointed to Allergan's Board of Directors  

Showing 1-20 of 31
Page: 1 2
 Next 20